Mr. Josh Spiegel reports

NETRAMARK SIGNS THIRD CONTRACT WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS

Netramark Holdings Inc. has signed a third contract with a large publicly listed biopharmaceutical company, pursuant to the master service agreement, previously announced on Oct. 31, 2023.

Netramark will employ its proprietary Attractor AI technology to analyze clinical trial data provided from the biopharmaceutical company's distinct phase II candidate medicine.

The primary objectives of the contract are as follows:

• Perform an analysis with NetraAI based on variables derived from pertinent factors collected between screening and baseline;
• Based on the NetraAI analysis of such data, patients will be labelled according to their level of response to placebo and drug based on accepted standards for this disease category; variables collected early in the trial will be used by NetraAI to generate explanatory models of subpopulations as they pertain to drug and placebo response;
• NetraAI will produce personas, which are driving factors behind precise groups of patients, that are directly related to drug and placebo response; NetraAI will also be provided with other questions to analyze through other various related measures as requested by the sponsor.

Netramark will then create a synopsis of all personas that emerge from the aforementioned analyses and evaluate the stability of the driving factors and sets of patients as defined by the aforementioned definitions. A report will be produced that provides critical information about:

• Drug and placebo response as determined by the end point measure, where response is defined by an industry-accepted change in total score from baseline or the imputed score as the sponsor study team sees fit;
• Hypotheses of response, which will be in the form of patient subpopulations, their response status, whether they are in the drug or placebo arm, along with explanatory variables for each;
• Adverse event (AE) modelling based on reported AEs, for which the company is relying on the sponsor team to clearly outline any AEs and to provide labelling for patients who experienced such events, if any;
• Factors that will lower the placebo response while simultaneously maximizing drug response;
• Inclusion/exclusion criteria presented in a table that outlines the feasibility and effect of each variable for any future enrichment process; this will provide a precise perspective into what is driving response to both drug and placebo, according to the set of variables that NetraAI will ingest.

"The company continues to expand its presence with a customer that has multiple clinical-stage assets, which ultimately reinforces the product/market fit of the Netramark offerings," said Josh Spiegel, president of Netramark. "We are continuing to aggressively build out our sales pipeline and are very excited about the momentum we are generating."

Netramark is strongly positioned to empower pharmaceutical companies and their respective contract research organizations (CROs) with critical scientific insights to accelerate speed, quality and accuracy across their clinical strategy protocol designs to help drive improved patient outcomes and operational results.

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of generative artificial intelligence/machine learning solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activate traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.